Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;70(5):348-350.
doi: 10.5455/medarh.2016.70.348-350. Epub 2016 Oct 25.

Association of Beta-2 Microglobulin with Inflammation and Dislipidemia in High-Flux Membrane Hemodialysis Patients

Valdete Topçiu-Shufta  1 , Ramë Miftari  2 , Valdete Haxhibeqiri  3 , Shpend Haxhibeqiri  2
Affiliations

Association of Beta-2 Microglobulin with Inflammation and Dislipidemia in High-Flux Membrane Hemodialysis Patients

Valdete Topçiu-Shufta et al. Med Arch. 2016 Oct.

Abstract

Background: Higher than expected cardiovascular mortality in hemodialysis patients, has been attributed to dyslipidemia as well as inflammation. Beta2-Microglobulin (β2M) is an independent predictor of outcome for hemodialysis patients and a representative substance of middle molecules.

Results: In 40 patients in high-flux membrane hemodialysis, we found negative correlation of β2M with high density lipoprotein (r=-0.73, p<0.001) and albumin (r= -0.53, p<0.001) and positive correlation with triglycerides (r=0.69, p<0.001), parathyroid hormone (r=0.58, p < 0.05) and phosphorus (r= 0.53, p<0.001). There was no correlation of β2M with C- reactive protein (CRP) and interleukin-6 (IL-6). During the follow-up period of three years, 6 out of 40 patients have died from cardiovascular events.

Conclusion: In high-flux membrane hemodialysis patients, we observed a significant relationship of β2M with dyslipidemia and mineral bone disorders, but there was no correlation with inflammation.

Keywords: beta-2 microglobulin; cardiovascular diseases; dyslipidemia; hemodialysis; inflammation.

PubMed Disclaimer

Conflict of interest statement

• Conflict of interest: none declared.

References

    1. Sameiro Faria M, Ribeiro S, Costa E, et al. Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. Disease Markers. 2013;35(6):791–8. http://dx.doi.org/10.1155/2013/518945. - PMC - PubMed
    1. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62(5):1524–38. doi:10.1046/j.1523-1755.2002.00600. - PubMed
    1. Locatelli F, Gauly A, Czekalski S, et al. The MPO Study: just a European HEMO Study or something very different? Blood Purif. 2008;26(1):100–4. - PubMed
    1. Kazama J, Maruyama H, Gejyo F. Reduction of circulating b2-microglobulin level for the treatment of dialysis-related amyloidosis. Nephrol Dial Transplant. 2001;16(4):31–5. - PubMed
    1. Wilson AM, Kimura E, Harada RK, et al. B2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation. 2007;116(12):1396–1403. doi:10.1161/CIRCULATIONAHA.106.683722. - PubMed